secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2026-05-29T20:54:45+00:00
Accession:  0001628280-26-039233
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience stockholders approve 3x increase in authorized common shares to 300M
--------------------------------------------------------------------------------

- Charter Amendment increases authorized common shares from 100M to 300M, filed with Nevada on May 28, 2026.
- Approved at May 26 annual meeting: 20,594,286 for, 2,875,605 against, 59,533 abstain.
- All six director nominees elected including CEO Punit Dhillon, each >13M votes for.
- CBIZ CPAs P.C. ratified as independent auditor for FY 2026: 22,802,045 for, 542,634 against.
- Advisory 'say-on-pay' approved: 12,696,055 for, 909,925 against, with 9,823,126 broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000162828026039233/0001628280-26-039233-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000162828026039233/skye-20260526.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-039233

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer